US8715645B2
(en)
*
|
1994-05-27 |
2014-05-06 |
The Regents Of The University Of Colorado |
Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US20040047864A1
(en)
*
|
1996-03-14 |
2004-03-11 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule I
|
AU3381097A
(en)
*
|
1996-06-07 |
1998-01-05 |
Amgen, Inc. |
Tumor necrosis factor-related polypeptide
|
EP2314695A3
(de)
|
1996-12-23 |
2011-12-21 |
Immunex Corporation |
Ligand für Rezeptor Aktivator of NF-kappa B, Ligand ist Mitglied der TNF Superfamilie
|
EP1012274B2
(de)
|
1997-01-28 |
2011-06-15 |
Human Genome Sciences, Inc. |
"death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
|
US8329179B2
(en)
|
1997-01-28 |
2012-12-11 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
US6433147B1
(en)
|
1997-01-28 |
2002-08-13 |
Human Genome Sciences, Inc. |
Death domain containing receptor-4
|
US7452538B2
(en)
*
|
1997-01-28 |
2008-11-18 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
JP3813682B2
(ja)
*
|
1997-01-29 |
2006-08-23 |
小山 省三 |
ワクチン前駆体およびワクチン
|
US20020009467A1
(en)
|
1997-01-29 |
2002-01-24 |
Shozo Koyama |
Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
|
EP0977887A2
(de)
|
1997-02-12 |
2000-02-09 |
Abbott Laboratories |
Mitglied der tnf-familie verwendbar zur behandlung und diagnose von erkrankungen
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
US7528239B1
(en)
*
|
1997-02-13 |
2009-05-05 |
Immunex Corporation |
Receptor that binds trail
|
US20010010924A1
(en)
*
|
1997-03-14 |
2001-08-02 |
Keith Charles Deen |
Tumor necrosis factor related receptor, tr6 polynecleotides
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
AU747635B2
(en)
*
|
1997-03-17 |
2002-05-16 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20020102706A1
(en)
*
|
1997-06-18 |
2002-08-01 |
Genentech, Inc. |
Apo-2DcR
|
ES2284203T5
(es)
*
|
1997-04-16 |
2016-03-11 |
Amgen Inc. |
Proteínas de unión a osteoprotegerina y sus receptores
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
WO1998051793A1
(en)
*
|
1997-05-15 |
1998-11-19 |
Genentech, Inc. |
Apo-2 RECEPTOR
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
EP2083079A1
(de)
*
|
1997-06-18 |
2009-07-29 |
Genentech, Inc. |
Apo-2DcR
|
US6171787B1
(en)
*
|
1997-06-26 |
2001-01-09 |
Abbott Laboratories |
Member of the TNF family useful for treatment and diagnosis of disease
|
AU8400398A
(en)
*
|
1997-07-11 |
1999-02-08 |
Trustees Of The University Of Pennsylvania, The |
Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
|
FR2766713B1
(fr)
*
|
1997-08-04 |
1999-09-24 |
Bio Merieux |
Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
|
US6346388B1
(en)
|
1997-08-13 |
2002-02-12 |
Smithkline Beecham Corporation |
Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
|
US6440694B1
(en)
|
1997-09-30 |
2002-08-27 |
Pharmacia & Upjohn Company |
TNF-related death ligand
|
AU760010B2
(en)
*
|
1997-11-18 |
2003-05-08 |
Genentech Inc. |
DNA19355 polypeptide, a tumor necrosis factor homolog
|
US7019119B2
(en)
*
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
JP2002508962A
(ja)
*
|
1998-01-15 |
2002-03-26 |
ジェネンテク・インコーポレイテッド |
Apo−2リガンド
|
US20040120947A1
(en)
*
|
1998-01-26 |
2004-06-24 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
US20040180049A1
(en)
*
|
1998-01-26 |
2004-09-16 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
CA2324494A1
(en)
*
|
1998-03-27 |
1999-09-30 |
Genentech, Inc. |
Apo-2 ligand-anti-her-2 antibody synergism
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
ATE443723T1
(de)
*
|
1998-06-12 |
2009-10-15 |
Genentech Inc |
Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
|
AU771224B2
(en)
|
1998-07-13 |
2004-03-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
WO2000026228A1
(en)
*
|
1998-11-02 |
2000-05-11 |
Clontech Laboratories, Inc. |
Gene and protein for regulation of cell death
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
US7465785B2
(en)
*
|
1999-03-08 |
2008-12-16 |
Genentech, Inc. |
Polypeptide encoded by a nucleic acid over-expressed in melanoma
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
JP4716578B2
(ja)
|
1999-04-12 |
2011-07-06 |
ジェネンテック, インコーポレイテッド |
腫瘍壊死因子相同体及びそれをコードする核酸
|
WO2000063253A1
(en)
*
|
1999-04-16 |
2000-10-26 |
Amgen Inc. |
Agp-1 fusion protein compositions and methods
|
EP1820860A3
(de)
*
|
1999-06-02 |
2008-03-19 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
|
IL147029A0
(en)
|
1999-06-28 |
2002-08-14 |
Genentech Inc |
Method for making apo-2 ligand using divalent metal ions
|
CA2386002A1
(en)
*
|
1999-09-30 |
2001-04-05 |
The Trustees Of The University Of Pennsylvania |
Trail: an inhibitor of autoimmune inflammation and cell cycle progression
|
US6444640B1
(en)
*
|
1999-09-30 |
2002-09-03 |
Ludwig Institute For Cancer Research |
Compositions of trail and DNA damaging drugs and uses thereof
|
ES2433011T3
(es)
|
1999-12-20 |
2013-12-05 |
Immunex Corporation |
Receptor TWEAK
|
ATE481475T1
(de)
*
|
2000-01-24 |
2010-10-15 |
Univ Louisville Res Found |
Immunmodulation mit rezeptorinduziertem tod durch apoptosis
|
US7927602B2
(en)
|
2002-07-23 |
2011-04-19 |
University Of Louisville Research Foundation, Inc. |
Fas ligand-avidin/streptavidin fusion proteins
|
ATE329610T1
(de)
|
2000-02-16 |
2006-07-15 |
Genentech Inc |
Anti-april antikörper und hybridomazellen
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
IL151853A0
(en)
|
2000-04-11 |
2003-04-10 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
US6900185B1
(en)
|
2000-04-12 |
2005-05-31 |
University Of Iowa Research Foundation |
Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
|
CA2413237C
(en)
|
2000-06-30 |
2013-09-10 |
University Of Louisville Research Foundation, Inc. |
Alteration of cell membrane for new functions
|
EP1303293B1
(de)
|
2000-07-27 |
2008-12-03 |
Genentech, Inc. |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
DE10045591A1
(de)
*
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
KR20030055274A
(ko)
|
2000-10-20 |
2003-07-02 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 트롬보포에틴 아고니스트 항체
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
EP1339426A4
(de)
*
|
2000-11-08 |
2004-06-30 |
Human Genome Sciences Inc |
Antikörper mit immunspezifischer bindung an trail-rezeptoren
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
ES2437992T3
(es)
|
2001-05-25 |
2014-01-15 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
GB0113920D0
(en)
|
2001-06-07 |
2001-08-01 |
Sterix Ltd |
Composition
|
DK2270052T3
(en)
|
2001-06-26 |
2018-07-02 |
Amgen Inc |
Antibodies to OPGL
|
DE60232660D1
(de)
|
2001-07-03 |
2009-07-30 |
Genentech Inc |
Humane dr4-antikörper und deren anwendungen
|
US20030082722A1
(en)
*
|
2001-08-08 |
2003-05-01 |
Bingliang Fang |
Method for amplifying expression from a cell specific promoter
|
JP2005508162A
(ja)
*
|
2001-10-02 |
2005-03-31 |
ジェネンテック・インコーポレーテッド |
Apo−2リガンド変異体とその使用法
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
AU2007200478A1
(en)
*
|
2001-11-13 |
2007-02-22 |
Genentech, Inc. |
APO2 ligand/trail formulations
|
PT1450847E
(pt)
|
2001-11-13 |
2011-01-05 |
Genentech Inc |
Formulações de ligando de apo2/trail e suas utilizações
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
US20030180296A1
(en)
*
|
2001-12-20 |
2003-09-25 |
Theodora Salcedo |
Antibodies that immunospecifically bind to trail receptors
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
MXPA04009681A
(es)
*
|
2002-04-05 |
2005-01-11 |
Amgen Inc |
Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
|
AU2003247609A1
(en)
|
2002-06-24 |
2004-01-06 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
DK2269656T3
(da)
|
2002-07-15 |
2014-11-03 |
Univ Texas |
Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
|
WO2004052292A2
(en)
*
|
2002-12-06 |
2004-06-24 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
WO2008109433A2
(en)
|
2007-03-02 |
2008-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
US20070258972A1
(en)
*
|
2003-09-18 |
2007-11-08 |
Atadja Peter W |
Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand
|
ATE501256T1
(de)
|
2003-11-03 |
2011-03-15 |
Beijing Sunbio Biotech Co Ltd |
Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
|
EP1710255A4
(de)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
|
KR101535395B1
(ko)
|
2004-01-22 |
2015-07-08 |
유니버시티 오브 마이애미 |
국소용 코-엔자임 큐10 제형 및 그의 사용 방법
|
US20080242603A1
(en)
*
|
2004-02-20 |
2008-10-02 |
Yan Wang |
Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
|
JP5014116B2
(ja)
|
2004-03-11 |
2012-08-29 |
ジェネンテック, インコーポレイテッド |
ポリペプチドの精製
|
BRPI0509201A
(pt)
|
2004-03-23 |
2007-08-28 |
Biogen Idec Inc |
agentes de acoplamento de receptor e usos terapêuticos destes
|
CA2575152A1
(en)
|
2004-08-06 |
2006-02-16 |
Genentech, Inc. |
Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
|
EP1774037B1
(de)
*
|
2004-08-06 |
2011-05-11 |
Genentech, Inc. |
Assays und verfahren unter verwendung von biomarkern
|
CN101048428A
(zh)
*
|
2004-09-08 |
2007-10-03 |
健泰科生物技术公司 |
利用死亡受体配体和cd20抗体的方法
|
WO2006029224A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Genentech, Inc. |
Methods of using death receptor ligands and cd20 antibodies
|
EP1645875A1
(de)
*
|
2004-10-08 |
2006-04-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Diagnose und Therapie von Zellproliferationskrankheiten die durch TRAIL Resistenz Apoptose gekennzeichnet sind
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US20060228352A1
(en)
*
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc(Fv)2構造異性体
|
KR101360671B1
(ko)
|
2005-06-10 |
2014-02-07 |
추가이 세이야쿠 가부시키가이샤 |
sc(Fv)2를 함유하는 의약조성물
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
EP1915626B1
(de)
|
2005-08-16 |
2011-11-09 |
Genentech, Inc. |
Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
|
AU2006283174A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell-Matrix, Inc. |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
PE20071101A1
(es)
*
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
GB0524316D0
(en)
*
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
US20100047783A1
(en)
*
|
2006-06-20 |
2010-02-25 |
El-Diery Wafik S |
Small molecule modulators of p53 family signaling
|
WO2008088582A2
(en)
*
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
CA2963124C
(en)
|
2007-07-10 |
2019-10-15 |
Apogenix Ag |
Tnf superfamily collectin fusion proteins
|
AU2013203061B2
(en)
*
|
2007-07-10 |
2016-07-28 |
Apogenix Ag |
TNF superfamily collectin fusion proteins
|
WO2009025743A2
(en)
*
|
2007-08-17 |
2009-02-26 |
University Of Massachusetts Medical School |
Use of trail compositions as antiviral agents
|
CN101157729B
(zh)
*
|
2007-10-23 |
2011-01-12 |
南京大学 |
一种肿瘤坏死因子相关凋亡配体变体及其应用
|
JP5809415B2
(ja)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ,インコーポレーテッド |
抗vegf抗体の組成物および方法
|
JP5773879B2
(ja)
|
2008-11-25 |
2015-09-02 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
神経系の細胞の生存を促進するためのDR6およびp75のアンタゴニストの使用
|
WO2010078966A1
(en)
|
2009-01-09 |
2010-07-15 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
ES2356880B8
(es)
|
2009-08-21 |
2012-10-30 |
Universidad De Zaragoza |
Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
|
WO2011043835A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Anaphore, Inc. |
Polypeptides that bind il-23r
|
EP2556840B1
(de)
*
|
2010-04-01 |
2017-09-27 |
Korea Research Institute of Bioscience and Biotechnology |
Zusammensetzung zur erhöhung einer trail-empfindlichkeit mit einem hemmer zur hemmung der expression oder aktivität des trail-sensibilisierer-zielgens tip41
|
PL391627A1
(pl)
*
|
2010-06-25 |
2012-01-02 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
US9012178B2
(en)
|
2010-08-05 |
2015-04-21 |
Amgen Inc. |
Dipeptides to enhance yield and viability from cell cultures
|
JP5759557B2
(ja)
|
2010-12-03 |
2015-08-05 |
アダムド エスピー.ゼット オー.オー.Adamed Sp.Z O.O. |
抗がん融合タンパク質
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
PL394618A1
(pl)
|
2011-04-19 |
2012-10-22 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
WO2012145682A1
(en)
|
2011-04-21 |
2012-10-26 |
Amgen Inc. |
A method for culturing mammalian cells to improve recombinant protein production
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
EP2837680B1
(de)
|
2011-07-01 |
2020-02-26 |
Amgen Inc. |
Säugetierzellkultur
|
CN102908612A
(zh)
*
|
2011-08-02 |
2013-02-06 |
北京诺赛基因组研究中心有限公司 |
TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
|
US20140315187A1
(en)
|
2011-09-02 |
2014-10-23 |
Amgen Inc. |
Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
|
CN103534273B
(zh)
*
|
2011-09-16 |
2020-05-12 |
北京沙东生物技术有限公司 |
环化变构trail/apo2l及其编码基因与应用
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
PL223487B1
(pl)
|
2011-12-28 |
2016-10-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
US9511047B2
(en)
*
|
2012-12-11 |
2016-12-06 |
Sapiotec Gmbh |
Delphinidin for combating melanoma cells
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
US20160067337A1
(en)
|
2013-03-14 |
2016-03-10 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
TWI625390B
(zh)
|
2013-03-14 |
2018-06-01 |
安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
LT3395423T
(lt)
|
2013-03-14 |
2023-12-11 |
Amgen Inc. |
Pratekančių giminingumo gryninimo ligandų pašalinimas
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
KR20200108903A
(ko)
|
2013-06-25 |
2020-09-21 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
CN103555729B
(zh)
*
|
2013-10-14 |
2016-08-24 |
成都华创生物技术有限公司 |
一种改造的trail基因序列、表达方法及应用
|
JP6621744B2
(ja)
|
2013-10-31 |
2019-12-18 |
アムジエン・インコーポレーテツド |
組換えタンパク質のグリコシル化を調節するためのモネンシンの使用
|
JP6732660B2
(ja)
|
2014-01-13 |
2020-07-29 |
アムジエン・インコーポレーテツド |
組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
SG10201912081RA
(en)
|
2014-01-29 |
2020-02-27 |
Amgen Inc |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
FI3926051T3
(fi)
|
2014-06-04 |
2024-06-18 |
Amgen Inc |
Menetelmiä nisäkässoluviljelmien keräämiseksi
|
ES2727380T3
(es)
|
2014-11-19 |
2019-10-15 |
Amgen Inc |
Cuantificación de resto glucano en glucoproteínas recombinantes
|
LT3227454T
(lt)
|
2014-12-01 |
2020-07-27 |
Amgen Inc. |
Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
JP7008023B2
(ja)
|
2015-12-30 |
2022-01-25 |
ジェネンテック, インコーポレイテッド |
低減されたポリソルベート分解を有する製剤
|
CN109415740A
(zh)
*
|
2016-02-05 |
2019-03-01 |
斯比根公司 |
表达trail和cd的间充质干细胞及其用途
|
WO2017177148A1
(en)
|
2016-04-07 |
2017-10-12 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
KR101739703B1
(ko)
*
|
2016-09-13 |
2017-05-24 |
(주) 어드밴스드 엔티 |
Trail 기반 뇌염 감별진단 방법 및 장치
|
US11519007B2
(en)
|
2019-02-22 |
2022-12-06 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
|
CA3241882A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|